Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on <sup>18</sup>F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma

<div class="floats-full-page floats-full-page-other"><h2>Table 1</h2><div class="floats-full-page-caption"><div>Characteristics of 84 RPLS patients in the study.</div></div><div class="floats-full-page-content"><table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr /></td></tr><tr class="thead"><td class="align_left">Characteristics</td><td class="align_center">No.</td><td class="align_center">%</td></tr><tr><td class="thead-hr" colspan="3"><hr /></td></tr><tr><td class="align_left" colspan="3">Age (years)</td></tr><tr><td class="align_left"> Median (range)</td><td class="align_center">57 (29–81)</td><td class="align_center"> </td></tr><tr><td class="align_left" colspan="3">Sex</td></tr><tr><td class="align_left"> Male</td><td class="align_center">47</td><td class="align_center">56.0</td></tr><tr><td class="align_left"> Female</td><td class="align_center">37</td><td class="align_center">44.0</td></tr><tr><td class="align_left" colspan="3">Presentation</td></tr><tr><td class="align_left"> Primary</td><td class="align_center">46</td><td class="align_center">54.8</td></tr><tr><td class="align_left"> Recurrent</td><td class="align_center">38</td><td class="align_center">45.2</td></tr><tr><td class="align_left" colspan="3">Tumor size (cm)</td></tr><tr><td class="align_left"> Median (range)</td><td class="align_center">23 (4.6–50)</td><td class="align_center"> </td></tr><tr><td class="align_left" colspan="3">Subtype</td></tr><tr><td class="align_left"> WDLPS</td><td class="align_center">19</td><td class="align_center">22.6</td></tr><tr><td class="align_left"> DDLPS</td><td class="align_center">60</td><td class="align_center">71.4</td></tr><tr><td class="align_left"> PMLPS</td><td class="align_center">5</td><td class="align_center">6.0</td></tr><tr><td class="align_left" colspan="3">FNCLCC grade</td></tr><tr><td class="align_left"> G1</td><td class="align_center">16</td><td class="align_center">19.0</td></tr><tr><td class="align_left"> G2</td><td class="align_center">37</td><td class="align_center">44.0</td></tr><tr><td class="align_left"> G3</td><td class="align_center">31</td><td class="align_center">37.0</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr" /></td></tr></table></td></tr></table></div></div>

Table 1 | Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on <sup>18</sup>F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma

title

Table 1: Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on <sup>18</sup>F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma

description

Table 1 | Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on 18F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma

Table 1

About this journal

<p><em>Contrast Media &amp; Molecular Imaging</em>&nbsp;is an exciting journal in the area of contrast agents and molecular imaging, covering all areas of imaging technologies with a special emphasis on&nbsp;MRI and PET.</p>


Journal profile

Meet the editorial board

<p>Chief Editor, Professor Zimmer, focuses&nbsp;on the development and use of PET radiotracers for new applications of PET/MRI imaging in neuroscience and pharmacology.</p>


Editor spotlight

Submit your proposal

Do you think there is an emerging area of research that really needs to be highlighted? Or an existing research area that has been overlooked or would benefit from deeper investigation? Raise the profile of a research area by leading a Special Issue.

Contrast Media & Molecular Imaging

Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on ¹⁸F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma

Table 1